Design (DSGN) Rises 7.44% on June 21

Equities Staff  |

Design Therapeutics Inc (NASDAQ: DSGN) shares moved 7.44%, or $1.05 per share, as on 11:52:07 est today. Since opening the day at $13.30, 52,452 shares of Design have traded hands and the stock has ranged between $15.31 and $14.36.  

Already this year the company has a YTD change of 34.10%.

Design expects its next earnings on 2022-08-08.

For technical charts, analysis, and more on Design visit the company profile.

About Design Therapeutics Inc

Design Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, followed by a program in myotonic dystrophy type-1 and discovery efforts for multiple other serious degenerative disorders caused by nucleotide repeat expansions.

To get more information on Design Therapeutics Inc and to follow the company's latest updates, you can visit the company's profile page here: Design Therapeutics Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content